Drug
Lutetium-177 clinical trials
- studies test it
- 36
- open now
- 23
- in phase 3
- 3
- first study started
- 2022
Keep track of what changes. Save the Lutetium-177 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
36 studies that test it; most in 2024 (10)
| Year | Studies |
|---|---|
| 2022 | 4 |
| 2023 | 8 |
| 2024 | 10 |
| 2025 | 5 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 8
- Phase 1
- 18
- Phase 2
- 13
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 20 · Other 16
Novartis Pharmaceuticals (8) · Sinotau Pharmaceutical Group (3) · Beijing Tiantan Hospital (2) · Sichuan Baili Pharmaceutical Co., Ltd. (2) · Nantes University Hospital (1) · Providence Health & Services (1) · Advanced Accelerator Applications (1) · Tomsk National Research Medical Center of the Russian Academy of Sciences (1)
Often tested with
Tested in the same studies.
Capecitabine (1) · Lutetium Lu 177 dotatate (1) · Metoclopramide (1) · Ribociclib (1) · Fulvestrant (1) · Cabozantinib (1) · Actinium-225 (1) · Gallium-68 (1)
Studies
Open first, then newest update. How each study uses Lutetium-177 is read from its arms, and is right about nine times in ten.
Testing it · 36
- Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior TreatmentRecruitingPhase 2RTOG Foundation, Inc.NCT06955169Written as [177Lu]Lu-DOTATATE
- A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsRecruitingPhase 1Alpha-9 Oncology USA Inc.NCT07661641Written as [177Lu]Lu-A9-0631
- Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid TumorsRecruitingPhase 1Novartis PharmaceuticalsNCT07660055Written as [177Lu]Lu-DWJ155
- Evaluation of Targeted Radionuclide Therapy of Lu-177 PSMA in Patients With Compromised Renal and/or Bone Marrow FunctionRecruitingPhase 4M.D. Anderson Cancer CenterNCT07169825Written as Lu-177
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersRecruitingPhase 1Novartis PharmaceuticalsNCT06562192Written as [177Lu]Lu-NNS309
- A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine NeoplasmsRecruitingPhase 2/3Sinotau Pharmaceutical GroupNCT06398444Written as Lutetium[177Lu] Oxodotreotide Injection
- Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung CancerRecruitingEarly Phase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07689643Written as [177Lu]Lu-RTX-2358
- [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade GliomaRecruitingEarly Phase 1Beijing Tiantan HospitalNCT07655869Written as [177Lu]Lu-DOTA-EB-RGD2
- Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent GlioblastomaRecruitingEarly Phase 1Beijing Tiantan HospitalNCT07648823Written as [177Lu]Lu-XT771
- First-in-human Diagnostic Imaging Profile of the Theranostic Pair [68Ga]Ga-DOTA-STR-17126 and Low Dose [177Lu] Lu-DOTA-STR-17126 in Patients With Advanced or Metastatic CancerRecruitingEarly Phase 1Integrated Haematology and Oncology NetworkNCT07608848Written as [177Lu]Lu-DOTA-STR-17126
- An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.RecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05884255Written as Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
- [177Lu]Lu-AKIR001 First-in-human StudyRecruitingEarly Phase 1Karolinska University HospitalNCT06639191Written as [177Lu]Lu-AKIR001
- A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07232407Written as Lutetium [177Lu] BL-ARC001
- Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate CancerRecruitingPhase 2Hospices Civils de LyonNCT06866938Written as [177Lu]Lu-PSMA-617 (Pluvicto, Novartis)
- A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Sichuan Baili Pharmaceutical Co., Ltd.NCT07274852Written as Lutetium [177Lu] BL-ARC001
- A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced CancerRecruitingPhase 1/2Spago Nanomedical ABNCT06184035Written as [177Lu]Lu-SN201
- A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast CancerRecruitingPhase 1AffibodyNCT07081555Written as [177Lu]Lu-ABY-271
- A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate CancerRecruitingPhase 1Jinming ZhangNCT07096128Written as [177Lu]Lu-PSMA-XT
- A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid TumorsNot yet recruitingPhase 1Fudan UniversityNCT06553846Written as Lutetium [177Lu]-FAP-75
- Study of [177Lu]Lu-PSMA-137 In Metastatic Castrate Resistant Prostate Cancer（mCRPC）Not yet recruitingEarly Phase 1Peking University First HospitalNCT06546527Written as [177Lu]Lu-PSMA-137
See all 36 studies that test Lutetium-177 →
Given in every arm · 4 — Lutetium-177 is usual care beside what is tested
- Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate CancerRecruitingPhase 1Cellbion Co., Ltd.NCT07244393Written as Lutetium (177Lu) DGUL
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 InjectionRecruitingPhase 1/2Blue Earth Therapeutics LtdNCT05413850Written as Lutetium (177Lu) rhPSMA-10.1 Injection
- A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid TumorsRecruitingPhase 1Philogen S.p.A.NCT06640413Written as [177Lu]Lu-OncoFAP-23
- Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent GlioblastomaActive, not recruitingPhase 1Novartis PharmaceuticalsNCT05739942Written as [177Lu]Lu-NeoB
Codes
What other systems call Lutetium-177 · ClinicalTrials.gg INT000625
- MeSH (NLM) C000615061Lutetium-177Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) BRH40Y9V1QLUTETIUM LU-177Confirmed NLM, Wikidata
- Wikidata Q18882670lutetium-177Confirmed NLM, Wikidata
- DrugBank DB13982One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000615061 | Lutetium-177 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | BRH40Y9V1Q | LUTETIUM LU-177 | Confirmed NLM, Wikidata |
| Wikidata | Q18882670 | lutetium-177 | Confirmed NLM, Wikidata |
| DrugBank | DB13982 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.